Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 2/2016

10.02.2016 | Review Article

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

verfasst von: Sanket S. Mehta, Maxilliano Gelli, Deepesh Agarwal, Diane Goéré

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The combined treatment concept of cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown to be an efficient therapeutic option for selected patients with primary and secondary peritoneal carcinomatosis (PC). This strategy represents the standard of care for diseases like pseudomyxoma peritonei and peritoneal mesothelioma, and offers the best long-term results for PC from colorectal cancer. Despite these results, skepticism exists regarding this therapeutic approach partly because of its perceived high toxicity. In this article, we review the current evidence on complications that can occur after CRS and HIPEC and the risk factors associated with increased incidence of morbidity and mortality.
Literatur
1.
Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7(1):69–76CrossRefPubMed
2.
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456CrossRefPubMed
3.
Yan T, Welch L, Black D, Sugarbaker P (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834CrossRefPubMed
4.
Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13(2):229–237CrossRefPubMed
5.
Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432CrossRefPubMed
6.
Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 139(1):20–26CrossRefPubMed
7.
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27(5):681–685CrossRefPubMed
8.
Shen P, Thai K, Stewart JH, Howerton R, Loggie BW, Russell GB, et al. (2008) Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 15(12):3422–3432CrossRefPubMed
9.
Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94(11):1408–1414CrossRefPubMed
10.
Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy–a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 14(8):2270–2280CrossRefPubMed
11.
Moran BJ (2006) Decision-making and technical factors account for the learning curve in complex surgery. J Public Health 28(4):375–378CrossRef
12.
Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. (1996) Pseudomyxoma peritonei syndrome. Adv Surg 30:233–280PubMed
13.
Casado-Adam A, Alderman R, Stuart OA, Chang D, Sugarbaker PH (2011) Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol 2011:468698PubMedPubMedCentral
14.
Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10(8):863–869CrossRefPubMed
15.
Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106(5):1144–1153CrossRefPubMed
16.
Hansson J, Graf W, Pahlman L, Nygren P, Mahteme H (2009) Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 35(2):202–208CrossRefPubMed
17.
Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2011) Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum 54(3):293–299CrossRefPubMed
18.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618CrossRefPubMed
19.
Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M (2010) Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol 2(1):36–43CrossRefPubMedPubMedCentral
20.
Downs-Canner S, Ding Y, Magge DR, Jones H, Ramalingam L, Zureikat A, et al. (2015) A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol 22(5):1651–1657CrossRefPubMed
21.
Lawrence VA, Hilsenbeck SG, Mulrow CD, Dhanda R, Sapp J, Page CP (1995) Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med 10(12):671–678CrossRefPubMed
22.
Preti V, Chang D, Sugarbaker PH (2012) Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients. Gastroenterol Res Pract 2012:635314CrossRefPubMedPubMedCentral
23.
Sugarbaker P, Van der Speeten K, Stuart O, Chang D, Mahteme H (2012) Patient-and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Sugarbaker PH (ed) Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. Cine-Med, Connecticut
24.
Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH (2007) Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol 96(2):102–112CrossRefPubMed
25.
Chereau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E, et al. (2009) Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG 116(8):1062–1068CrossRefPubMed
26.
Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W (2008) Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol 109(2):303–307CrossRefPubMedPubMedCentral
27.
Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N (2007) Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol 96(6):507–513CrossRefPubMed
28.
Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6(8):790–796CrossRefPubMed
29.
Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P (2005) Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 31(1):53–58CrossRefPubMed
30.
Mohamed F, Moran BJ (2009) Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J 15(3):196–199CrossRefPubMed
31.
Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE, et al. (2004) Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 11(4):387–392CrossRefPubMed
32.
Muller H, Hahn M, Weller L, Simsa J (2008) Strategies to reduce perioperative morbidity in cytoreductive surgery. Hepato-Gastroenterology 55(86–87):1523–1529PubMed
33.
Schnake KJ, Sugarbaker PH, Yoo D (1999) Neutropenia following perioperative intraperitoneal chemotherapy. Tumori 85(1):41–46PubMed
34.
Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, et al. (2009) Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181–2187CrossRefPubMedPubMedCentral
35.
Becher RD, Shen P, Stewart JH, Russell G, Bradley JF, Levine EA (2011) Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol 2(2):70–76PubMedPubMedCentral
36.
Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179(1):e133–e139CrossRefPubMedPubMedCentral
37.
Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267–272CrossRefPubMed
38.
Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C, et al. (2010) A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 251(5):896–901CrossRefPubMed
39.
Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T (2014) The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 36(10):1486–1491CrossRefPubMed
40.
Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39(12):1435–1443CrossRefPubMed
41.
Vukadinovic V, Chiou JD, Morris DL (2015) Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience. Eur J Surg Oncol 41(5):702–706CrossRefPubMed
42.
Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag-Beaujard AC, Brigand C, et al. (2005) Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 48(7):1372–1379CrossRefPubMed
43.
Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol 22(9):2958–2964CrossRefPubMed
44.
Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRefPubMed
45.
van Vugt JL, Braam HJ, van Oudheusden TR, Vestering A, Bollen TL, Wiezer MJ, et al. (2015) Erratum to: Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol 22 Suppl 3:1610
46.
Saxena A, Yan TD, Chua TC, Morris DL (2010) Critical Assessment of Risk Factors for Complications after Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. Ann Surg Oncol 17(5):1291–1301CrossRefPubMed
Metadaten
Titel
Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases
verfasst von
Sanket S. Mehta
Maxilliano Gelli
Deepesh Agarwal
Diane Goéré
Publikationsdatum
10.02.2016
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2016
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-016-0504-6

Weitere Artikel der Ausgabe 2/2016

Indian Journal of Surgical Oncology 2/2016 Zur Ausgabe

Editorial Notes

Peritoneal Metastases: Prevention and Treatment

Preface

Preface

Review Article

Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review

Original Article

The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Review Article

Cytoreductive Surgery and Peritonectomy Procedures

Review Article

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

10.04.2024 | Narbenhernie | Nachrichten

Deutlich weniger Narbenhernien mit der Small-Bites-Technik
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.